Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
Stocks in this Quantisnow insightHealth Care
Quantisnow AI summary
Eton licensed Baylor IGF-1 spasm patents for ET-900; IND filed for Phase 2 in refractory epileptic spasms, first dosing Q1 2027.
Historical context for ETON
Across the 25 sessions after earlier ETON headlines, the stock closed higher 18 times and lower 7 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ETON | SPY |
|---|---|---|---|
| Oct 29, 2026 | Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026 | +3.6% | -0.4% |
| Sep 28, 2026 | Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules | +2.6% | -0.7% |
| Aug 27, 2026 | Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference | +0.1% | +0.7% |
| Aug 14, 2026 | Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results | +44.3% | -0.2% |
| Aug 5, 2026 | Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 | +0.3% | -0.2% |
| Aug 3, 2026 | Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 | -2.8% | +1.4% |
Quantisnow market dataNASDAQ
ETON
Eton Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for ETON
Full ETON profile on Quantisnow Follow ETON and get a push notification the moment its next story breaks.